A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
CLINICAL EFFECT OF TE-031 (A-56268) ON MALE URETHRITIS
TE-031の男子尿道炎に対する臨床効果
1988
Chemotherapy
TE-031の男子尿道炎に対する臨床効果
Preserved Fulltext
TE-031(A-56268), a new macrolide antibiotic, was evaluated for clinical efficacy and safety in 47 male patients with various kinds of urethritis. As a rule, in gonococcal urethritis, the drug was given orally in a dose of 400-800 mg/day b.i.d. before meals for 3-14 days. In non-gonococcal urethritis, 300-400 mg/day was given for 14 days. The effect of the drug was evaluated at the end of administration in both cases.
doi:10.11250/chemotherapy1953.36.supplement3_784
fatcat:ixtopbko4bcp3cnyi7g2lzvwaq